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Objectives The purpose of this study was to examine the clinical outcomes of using slow continuous ultrafiltration (SCUF) in
patients with acute decompensated heart failure (HF) refractory to intensive medical therapy.
Background Several studies have demonstrated the clinical usefulness of early SCUF in patients with acute decompensated
HF to improve fluid overload and hemodynamics.
Methods We reviewed clinical data from 63 consecutive adult patients with acute decompensated HF admitted to the
Heart Failure Intensive Care Unit from 2004 through 2009 who required SCUF because of congestion refractory
to hemodynamically guided intensive medical therapy.
Results The mean creatinine level was 1.9  0.8 mg/dl on admission and 2.2  0.9 mg/dl at SCUF initiation. After
48 hours of SCUF, there were significant improvements in hemodynamic variables (mean pulmonary arterial
pressure: 40  12 mm Hg vs. 33  8 mm Hg, p  0.002, central venous pressure: 20  6 mm Hg vs. 16  8
mm Hg, p  0.007, mean pulmonary wedge pressure: 27  8 mm Hg vs. 20  7 mm Hg, p  0.02, Fick car-
diac index: 2.2 l/min/m2 [interquartile range: 1.87 to 2.77 l/min/m2] vs. 2.6 l/min/m2 [interquartile range: 2.2
to 2.9 l/min/m2], p  0.0008), and weight loss (102  25 kg vs. 99  23 kg, p  0.0001). However, there
were no significant improvements in serum creatinine levels (2.2  0.9 mg/dl vs. 2.4  1 mg/dl, p  0.12) and
blood urea nitrogen (60  30 mg/dl vs. 60  28 mg/dl, p  0.97). Fifty-nine percent required conversion to
continuous hemodialysis during their hospital course, and 14% were dependent on dialysis at hospital discharge.
Thirty percent died during hospitalization, and 6 patients were discharged to hospice care.
Conclusions In our single-center experience, SCUF after admission for acute decompensated HF refractory to standard medi-
cal therapy was associated with high incidence of subsequent transition to renal replacement therapy and high
in-hospital mortality, despite significant improvement in hemodynamics. (J Am Coll Cardiol 2012;60:1906–12)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.957Despite aggressive diuresis during hospital admission for
acute decompensated heart failure (HF), only 52% of
patients derive symptomatic improvement after discharge
(1). Further, almost 16% of the patients gain rather than
lose weight during their hospitalizations, which may predict
subsequent rehospitalizations (2). These observations imply
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2012, accepted August 13, 2012.that diuretic therapy as a mainstay of therapeutic strategy
may provide inadequate relief of congestion in a subset of
patients. The underlying cause(s) of such insufficient salt
and volume removal is multifactorial. Underlying chronic
renal insufficiency may be more prevalent than appreciated
at the bedside (3) and can be exacerbated by adverse
hemodynamic alterations of HF or adverse consequences
See page 1913
related to aggressive diuretic therapy (4). Apparent diuretic
resistance also can be the result of reduced bioavailability of
oral loop diuretics or decreased renal tubular delivery (5).
Electrolyte disturbances associated with diuresis, such as
hyponatremia, hypokalemia, and hypomagnesemia, also
may limit effective diuresis (6).
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November 6, 2012:1906–12 Slow Continuous Ultrafiltration in Acute HFRecent data have suggested that the presence of signifi-
cant venous congestion can affect cardiorenal physiology
directly, independent of cardiac output, which can lead to
ineffective natriuresis (7,8). With the notion that the kid-
neys are unable to relieve downstream congestion effectively,
mechanical removal of salt and water became an attractive
concept in improving cardiac hemodynamics to facilitate
better renal perfusion. For example, the use of peritoneal
dialysis in the setting of refractory HF has long been
described (9–11). Recent studies also have shown the
potential benefit of slow continuous ultrafiltration (SCUF)
in early pre-emptive treatment of patients admitted with
volume overload secondary to acute decompensated HF,
with decreased hospitalization rates and improvement in
weight loss, exercise capacity, and filling pressures (12–16).
In subjects with advanced HF admitted for acute decom-
pensation, it often has been assumed that hemodynamic
compromise may drive insufficient diuretic and natriuretic
responses to diuretic therapy. However, whether such he-
modynamic improvement with ultrafiltration can consis-
tently translate into improvement in renal physiology and
function remains unproven. Herein, we review our single-
center experience with SCUF in patients with severely
decompensated HF, including the changes in cardiorenal
physiologic measurements during therapy and long-term
adverse outcomes. We hypothesize that hemodynamic im-
provements resulting from SCUF in the setting of persistent
congestion refractory to medical therapy may provide short-
term renal improvement.
Methods
Study population. We analyzed consecutive adult patients
admitted to the HF intensive care unit at the Cleveland
Clinic between January 2004 and June 2009 with acute
decompensated HF for hemodynamically guided therapy
who were refractory to standard medical therapy and who
had progressive oliguria or worsening renal function, despite
persistent congestion requiring nephrology consultation for
SCUF. We excluded patients who did not undergo SCUF
or who already had begun other methods of renal replace-
ment therapy at the time of admission, had a history of heart
or renal transplantation, had a pre-existing glomerular
filtration rate of 15 ml/min/1.73 m2 or less, or were without
history or diagnosis of HF. The Cleveland Clinic Insti-
utional Review Board approved the study.
emodynamic monitoring. We documented hemody-
amic information at the time of admission, SCUF initia-
ion, and 48 hours after SCUF initiation. The systolic and
iastolic blood pressures were obtained by sphygmomanom-
ter of the brachial artery, by peripheral arterial line mea-
urements, or both. Central venous pressure; systolic, dia-
tolic, and mean pulmonary arterial pressures; and
ulmonary capillary wedge pressure were assessed at the end
f expiration with a balloon-tipped catheter at steady state
ith the patient in the supine position. The cardiac index eas obtained by Fick equation
sing sampling of mixed central
enous blood gas obtained from
he pulmonary artery catheter.
he medications administered to
chieve these goals included any
ombination of diuretics, vasodi-
ators, and inotropic drugs, in ad-
ition to angiotensin-converting enzyme inhibitors,
ngiotensin-receptor blockers, beta-adrenergic blockers, and
ldosterone antagonists. Targeted optimal hemodynamic re-
ponse with SCUF and medical therapy was defined as a
ecrease in pulmonary capillary wedge pressure to 18 mm Hg
r less, a decrease in mean pulmonary arterial pressure by at
east 20%, a decrease in right atrial pressure to 8 mm Hg or
ess, and an improvement in cardiac index to 2.2 l/min/m2 or
ore, all while maintaining mean arterial pressure of more
han 65 mm Hg, as previously described (6).
ltrafiltration protocol. SCUF was performed using 2
ystems: either the Gambro Prisma systems with the M60
nd M100 sets (Gambro, Lakewood, Colorado), or the
xStage System 1 using the Express dialyzer set (NxStage
edical, Inc., Lawrence, Massachusetts). Vascular access
as gained with a central catheter in the femoral or jugular
ein. The blood flow rate ranged from 100 to 180 ml/min
nd the ultrafiltration rate ranged from 100 to 400 ml/h.
ltrafiltration rate adjustments and duration of therapy
ere driven by clinical and hemodynamic goals (volume
urden, respiratory status, systemic blood pressure, filling
ressures, and use of vasoactive drugs) by the caring neph-
ologists, in close collaboration with the cardiologists. Loop
iuretic therapy was continued in a subset of patients
particularly nonanuric patients), but in the large majority of
atients, loop diuretic therapy was withheld.
Paper records of all patients who underwent SCUF
uring the study period were reviewed carefully, and data
ere collected for all patients who underwent ultrafiltration
n the HF intensive care unit. Procedure-related data
ncluded: dates of initiation and termination of SCUF, filter
ype, anticoagulation used, blood flow rate, ultrafiltration
ate, and conversion to another method of renal replacement
herapy, such as continuous veno-venous hemodialysis or
ntermittent hemodialysis.
ata collection and outcome measures. Baseline data
ollection included demographic and clinical data, as well as
erial laboratory, echocardiographic, and hemodynamic data
efore ultrafiltration therapy as well as at 48 hours after
CUF initiation. The primary endpoint was all-cause mor-
ality as determined by documentation in the electronic
edical record and confirmed by the social security death
ndex. Secondary endpoints included number of readmis-
ions for acute decompensated HF and dialysis-dependent
tatus at the time of discharge.
tatistical analyses. Descriptive statistics were calculated
or the entire study population. Continuous variables were
Abbreviations
and Acronyms
HF  heart failure
IQR  interquartile range
SCUF  slow continuous
ultrafiltrationxpressed as mean SD if normally distributed and median
t
d
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mally distributed. Categorical variables were expressed as
proportion and frequencies. All between-subjects compari-
sons reported p values on the basis of 2-sided tests, and a p
value 0.05 was considered statistically significant. Kaplan-
Meier analysis for long-term survival was performed from
the time of initial SCUF date to time of death. The Cox
proportional hazards model was used as a univariate analysis
of the hazard ratio to determine the prognostic value
according to systolic blood pressure in this cohort. The
cutoff point of 110 mm Hg was selected on the basis of the
median systolic blood pressure value (rounded to the nearest
10 mm Hg). All statistical analyses were performed using
JMP software version 9.0 (SAS Institute, Cary, North
Carolina). All authors had full access to the data and take
responsibility for its integrity.
Results
Baseline characteristics. A total of 63 consecutive patients
who fulfilled inclusion and exclusion criteria were identified
during the study period. Baseline characteristics are pre-
sented in Table 1, whereas Table 2 lists baseline hemody-
namic measurements. These values were consistent with a
study population with advanced decompensated HF. The
Baseline CharacteristicsTable 1 Baseline Characteristics
Demographics
Median age (yrs) 58 (52–68)
Male (%) 76
White (%) 68
Black (%) 19
Hispanic/other (%) 13
Comorbidities (%)
Ischemic cardiomyopathy 60
Hypertension 62
Diabetes mellitus 60
Hyperlipidemia 70
Chronic kidney disease  stage III* 48
Medication before admission
Aspirin (%) 56
ACE inhibitor/ARB 45
Beta-blockers (%) 56
Digoxin (%) 26
Aldosterone antagonists (%) 37
Furosemide (%) 56
Furosemide mean dose (mg/day) 120 (65–190)
Other diuretics (%) 51
Inotropic drugs (%) 16
Echocardiographic data
LV ejection fraction (%) 26 15
LV end-diastolic dimension (cm) 5.9 1.1
LV end-systolic dimension (cm) 4.9 1.3
Moderate to severe RV dysfunction (%) 68
Values are n (range) or mean SD. *Defined as glomerular filtration rate60ml/min per 1.73m2
calculated by MDRD formula.
ACE  angiotensin-converting enzyme; ARB  aldosterone receptor blockers; LV  left ventric-
ular; RV  right ventricular.median 24-h urine output was 1,350 ml (IQR: 605 to 2,025
ml) before initiation of SCUF. Forty-eight patients (76%)
were treated in the hospital with furosemide with a median
daily dose of 480 mg (IQR: 240 to 480 mg), whereas 10
(16%) were taking additional metolazone and 15 (24%) were
taking additional chlorothiazide. Thirty-seven patients (59%)
were treated with intravenous vasoactive medications (includ-
ing 24 [38%] with dobutamine or milrinone and 13 [21%] with
nitroprusside, nitroglycerin, or both).
SCUF initiation. The mean time between admission and
consult to transfer to the HF intensive care unit was 5 days.
The mean time between admission and initiation of SCUF
was 8 days, with a mean ultrafiltration rate of 200 ml/hour
(IQR: 150 to 250 ml/h). The mean duration of SCUF for
the total cohort was 3  2 days. In the subset with
retrievable data for total fluid removal by SCUF (n  28),
here were no differences between those who needed versus
id not need transition to dialysis (p  0.76), nor between
those who died versus survived (p  0.28). Forty-five (71%)
patients underwent ultrafiltration more than 48 hours after
admission. In this subset, there were no significant changes
between admission and the date of SCUF initiation in terms
of body weight (98 kg [IQR: 87 to 119 kg] vs. 101 kg [IQR:
87.6 to 122.8 kg], p  0.75), mean arterial blood pressure
(76 mm Hg [IQR: 68 to 83 mm Hg] vs. 73 mm Hg [IQR:
68 to 82 mm Hg, p 0.76), mean pulmonary artery pressure
(39 mm Hg [IQR: 33 to 46 mm Hg] vs. 37 mm Hg
[IQR: 32 to 44 mm Hg], p  0.44), and central venous
pressure (23 mm Hg [IQR: 17 to 26 mm Hg] vs. 21 mm Hg
[IQR: 16 to 25 mmHg], p  0.1). This was despite
improvement in cardiac index (1.8 l/min/m2 [IQR 1.39–
.35 l/min/m2] vs. 2.2 l/min/m2 [IQR: 1.9 to 2.8 l/min/
m2], p  0.0006) and systemic vascular resistance (1,010
Clinical Characteristics atIntensive Care Un t AdmissionTable 2 Clinical Characteristics atIntensive Care Unit Admission
Clinical data
Weight (kg) 98 (86–117)
Systolic blood pressure (mm Hg) 108 (99–120)
Diastolic blood pressure (mm Hg) 62 (52–69.5)
Mean arterial blood pressure (mm Hg) 78 (68–85)
Mean pulmonary artery pressure (mm Hg) 40 (33–47.5)
Central venous pressure (mm Hg) 20 (16.5–26)
Mean pulmonary wedge pressure (mm Hg) 30 8
Fick cardiac index (l/minute per square meter) 1.8 (1.48–2.25)
Laboratory data
Blood urea nitrogen (mg/dl) 53 27
Creatinine (mg/dl) 1.9 0.8
Sodium (mmol/l) 133 6
Potassium (mmol/l) 4.1 0.7
Hematocrit (%) 35 4.8
Hemoglobin (g/dl) 11 1.7
Total protein (g/dl) 6.3 1.1
Albumin (g/dl) 3.7 0.8
Values are n (range) or mean  SD.dyn·s/cm5 [IQR: 699 to 1,377 dyn·s/cm5] vs. 855 dyn·s/cm5
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bserved that patients who began SCUF more than 48 h
fter admission had worsened hyponatremia (133  6
mol/dl vs. 131  7 mmol/dl, p  0.009), worsened
nemia (hemoglobin: 11  1.7 mg/dl vs. 9.5  1.5 mg/dl,
 0.0001), and worsening renal function (serum creati-
ine: 1.9  0.8 mg/dl vs. 2.4  0.9 mg/dl, p  0.0001;
lood urea nitrogen: 55  25 mg/dl vs. 64  29 mg/dl,
 0.002) from admission to the time of SCUF initiation.
In the overall cohort after 48 hours of SCUF, there was
significant weight loss (from 100 kg [IQR: 89 to 120 kg]
o 94 kg [IQR: 83 to 115 kg], p  0.0001), which was
ssociated with a significant improvement in hemodynamic
ariables (Fig. 1) accompanying a negative fluid balance of 5.7
.8 l after 48 h from SCUF initiation. However, there were
o improvements in renal indices observed, despite evidence
f hemoconcentration with a rise in total protein content
Table 3).
dverse outcomes. Figure 2 demonstrates the long-term
dverse outcomes for our study cohort. At the nephrology
onsult’s subsequent recommendation, 37 patients (59%)
ere switched from SCUF to continuous hemodialysis
continuous veno-venous hemodialysis). Within this subset
ho required continuous veno-venous hemodialysis, 16
ubjects died during hospitalization, 4 were discharged to
ospice care, and 9 subjects became dependent on dialysis
n discharge. In this subset, 93% were readmitted to the
ospital within 60 days from discharge.
In our overall study cohort, 19 subjects died during the index
Figure 1 Changes in Hemodynamics Before and After Slow Con
Graphs showing changes in hemodynamics before and after slow continuous ultra
(B) changes in central venous pressure, (C) changes in pulmonary wedge pressurospitalization, whereas 4 were discharged to hospice care. Theost likely cause of in-hospital mortality was progressive pump
ailure (73%), whereas no deaths were attributable to complica-
ions resulting from the SCUF procedure. The overall 1-year
ll-cause mortality was 70%, whereas 2 of the surviving patients at
year underwent orthotopic heart transplantation.
We further observed lower systolic blood pressure at the
ime of admission in patients who died within 30 days
ersus those who were alive at 30 days (99  25 mm Hg vs.
13  15 mm Hg, p  0.02). In univariate analysis, systolic
lood pressure had a hazard ratio of 0.5 (95% confidence
nterval: 0.008 to 0.8), with a 30-day mortality rate of 54%
bserved in patients undergoing SCUF in this setting with
ystolic blood pressure of 110 mm Hg or less at admission (Fig. 3).
us Ultrafiltration
n (SCUF): (A) changes in pulmonary artery pressure,
(D) changes in Fick cardiac index.
Changes in Laboratory DataAfter Slow Continuous Ultr filtrationTable 3 Cha ges in Laboratory DataAfter Slow Continuous Ultrafiltration
Before SCUF 48 h After SCUF p Value
Blood urea nitrogen (mg/dl) 60 31 61 29 0.97
Creatinine (mg/dl) 2.2 0.9 2.4 1 0.12
Sodium (mmol/l) 131 6.7 131 7 0.51
Potassium (mmol/l) 4.2 0.6 4.4 0.4 0.03
Hematocrit (%) 31 4.3 31 4 0.6
Hemoglobin (g/dl) 9.9 1.5 9.9 1.5 0.71
Protein total (g/dl) 5.9 1.2 6.6 0.6 0.006
Albumin (g/dl) 3.6 1.2 3.3 0.4 0.8tinuo
filtratio
e, andValues are mean SD.
SCUF  slow continuous ultrafiltration.
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This study represents our single-center clinical experience of
a large cohort of patients with advanced HF undergoing
SCUF as rescue therapy. The key finding of our study was
that the initiation of SCUF to relieve congestion as a result
of progressive cardiorenal compromise in our cohort of
patients admitted with refractory advanced HF may provide
significant hemodynamic improvement. Nevertheless, we
observed no significant improvement in renal function
before or after SCUF, despite effective salt and water
removal, and our patient cohort demonstrated high rates of
adverse clinical events and the need for renal replacement
therapy. Therefore, our findings refuted our original hy-
pothesis that hemodynamic improvement with SCUF in-
variably can translate into direct cardiorenal improvement
and cautioned the promise of potential benefit of SCUF in
the setting of advanced decompensated HF refractory to
medical therapy. In particular, there is a need to discuss
thoroughly the relatively poor long-term prognosis with the
patient especially in the setting of low systemic blood
pressure, even though transient hemodynamic improve-
ments can be achieved.
Figure 2 Clinical Outcomes of Study Cohort After SCUF
CVVHD  continuous veno-venous hemodialysis; HF  heart failure; RRT  renal
Figure 3 30-Day Mortality in Relationship
to Systolic Blood Pressure at AdmissionThis study presents a counterpoint to the optimistic
expectations of remarkable benefits of mechanical salt and
water removal in previous studies (13–16), in particular to
be put in the context of a very different clinical situation in
which SCUF provides temporary relief in a salvage manner,
despite remarkable improvement in central hemodynamics.
It is important to acknowledge that this is a patient
population with advanced HF admitted for acute decom-
pensated HF refractory to standard medical therapy in
which SCUF has not been tested prospectively in random-
ized clinical trials. There are several important differences in
the use of SCUF between our series and that reported in the
UNLOAD (Ultrafiltration Versus Intravenous Diuretics for
Patients Hospitalized for Acute Decompensated Heart
Failure) study (16). First and foremost, patients in our
cohort had markedly impaired hemodynamic measure-
ments at admission and required more vasoactive thera-
pies compared with other SCUF studies (76% vs. 3% in
the UNLOAD study) (16). Second, there was a delay in
SCUF initiation after failed attempts to relieve congestion
by medical therapy in our study compared with immediate
SCUF after admission in the UNLOAD study as pre-
emptive treatment (16). Whether a more upfront approach
can translate into clinical benefits in an adequately powered
study in an acute decompensated HF patient population
with evidence of renal vulnerability, rather than refractori-
ness, will be tested in the upcoming CARRESS-HF (CAR-
diorenal REScue Study in Acute Decompensated Heart
Failure) trial (NCT00608491) (17).
One of the prevailing hypotheses regarding the patho-
genesis of acute cardiorenal syndrome has been attributed to
altered hemodynamics, whereby a decrease in blood flow to
the kidneys leads directly to renal impairment. Furthermore,
we and others previously demonstrated that venous conges-
tion is associated with cardiorenal compromise in patients
with advanced decompensated HF (6,7). In our study
cohort, SCUF successfully produced a significant weight
loss (mean weight loss: 4.4 kg vs. 5.0 kg in the UNLOAD
ment therapy; other abbreviation as in Figure 1.replacetrial) (16), coupled with significant improvements in venous
1911JACC Vol. 60, No. 19, 2012 Patarroyo et al.
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total protein levels (a surrogate of hemoconcentration). It
therefore is logical that such observed improvements may
lead directly to improvement in renal function. Instead,
we observed no significant changes in serum creatinine or
blood urea nitrogen levels in our study cohort; 53%
required in-hospital dialysis and 14% of patients were
dependent on dialysis at the time of discharge. Although
patients were evaluated after 48 h of SCUF, the fact that
a subset of patients warranted subsequent renal replace-
ment therapy also argued against a delayed recovery of
renal function in response to decongestion. Taken to-
gether, our observations imply that intrinsic renal impair-
ment likely is a major determinant of disease progression in
advanced HF.
Our findings are consistent with recent studies that have
challenged the central doctrine of hemodynamics (at least
when measured at the level of the central circulation) as the
primary determinant of acute cardiorenal syndrome. Specif-
ically in the ESCAPE (Evaluation Study of Congestive
Heart Failure and Pulmonary Artery Catheterization Effec-
tiveness) trial, baseline hemodynamic parameters may not
be significantly different between patients with no change in
renal function and patients with worsening renal function
(18). Furthermore, improvement in hemodynamic parame-
ters may not be closely linked with improvement in renal
function (19). The high event rates in our study cohort,
despite significant improvements in hemodynamics, also
mirrored the primary results of the ESCAPE trial showing
the lack of a relationship between improvement in central
hemodynamics and survival after discharge from the hospi-
tal with advanced HF (20). Hence, effective relief of venous
congestion, augmentation of cardiac output, reduction in
intracardiac filling pressures, or a combination thereof
cannot be translated uniformly into a more favorable and
sustainable renal improvement. If improving cardiac func-
tion does not occur through the kidney, and improving the
kidney function does not arise as a result of cardiac manip-
ulation, perhaps we should look for improvements in disease
mechanisms that are common to both, yet dependent on
neither.
Although there were very low short-term and long-term
mortality rates in the UNLOAD trial, a previously reported
single-center series of SCUF therapy reported an in-
hospital mortality of 11% and 1-year mortality of 39% (21).
In contrast, given that ultrafiltration or dialysis after a
patient has demonstrated resistance to all other therapies is
a treatment of desperation, the in-hospital mortality rate in
our series was 30%, and the overall 1-year mortality rate was
70%. The need to proceed with SCUF in our patient
population as a rescue strategy clearly represented a patient
population who were refractory to the standard medical
therapy of loop diuretics, similar to a previously reported
series (22). Among all the baseline hemodynamic variables,
we observed that systolic blood pressure at admission was an
important predictor of long-term survival, which is consis-tent with other large datasets (23). A decrease in systemic
blood pressure may represent an inability to generate suffi-
cient forward flow that likely will affect renal perfusion,
leading to worsening renal function and potentially inade-
quate congestion relief (24). With SCUF, a marginal blood
pressure may be intolerant to fluid removal, with a probable
blunted response to intravascular depletion that may be
reflected by lower perfusion to vital organs including the
heart and kidneys.
Study limitations. There are several limitations in our
single-center report. The purpose of the study was not to
examine the effectiveness of SCUF versus that of conven-
tional therapy, but rather to characterize the impact of
SCUF as a rescue therapy currently used in the setting of
acute (type 1) cardiorenal syndrome on hemodynamic,
renal, and outcome measures. Therefore, we did not have a
matched control group in part because of the inherent
selection bias of comparator groups. Furthermore, we have
no objective and reliable determination of preadmission
intrinsic renal function to determine the threshold by which
SCUF therapy may not result in significant improvement in
clinical outcomes, nor do we have complete data to examine
the relationship between hemodynamic and renal improve-
ment beyond 48 h of SCUF. We also acknowledge that
aggressive salt and water removal may produce a hemocon-
centration effect that may affect serum creatinine levels as
observed in the UNLOAD study (16). In addition, we
cannot account for inherent differences in the 2 machines
(gravimetric vs. volumetric controls), although the rate
adjustments were driven by clinical and hemodynamic
parameters, rather than a predetermined specific ultrafiltra-
tion rate. Furthermore, we cannot ignore the fact that
alternative approaches to relieve significant congestion be-
yond acute SCUF have been described. Nevertheless, our
observations demonstrated that initiation of SCUF in pa-
tients with advanced HF refractory to medical therapy
identifies an exceedingly high-risk patient category—with
no clear therapeutic options and the high likelihood of
conversion to renal replacement therapy as well as poor
outcome. Yet, the question of futility of an otherwise
invasive and demanding therapy is being raised on the basis
of our contemporary experience of the current rescue ther-
apy approach for SCUF. This is the first time such a series
of patients has been reviewed with respect to cardiorenal
outcomes—many of whom were not classic end-stage renal
disease patients. As clinicians caring for these patients, our
findings provided much-needed information to guide the
decision-making process in initiating SCUF in the setting
of refractory advanced HF, particularly regarding long-term
expectations.
Conclusions
In our single-center experience, the use of SCUF in patients
with advanced HF demonstrated significant hemodynamic
improvement, despite a lack of substantial renal improve-
1912 Patarroyo et al. JACC Vol. 60, No. 19, 2012
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sure at admission, the goal to relieve congestion temporarily
using this invasive strategy must be balanced carefully with
the persistent burden in long-term morbidity and mortality
in this population. In our contemporary experience, the
need for SCUF clearly marks an advanced HF status with
limited treatment options and poor outcomes, which are
important to convey to patients when treatment decisions
are being considered.
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